Intravenous immunoglobulin inhibits NF-κB activation and affects Fcγ receptor expression in monocytes/macrophages
High-dose intravenous immunoglobulin (IVIG) therapy is well established as a standard therapy for Kawasaki disease (KD) that reduces the risk of developing coronary artery aneurysms. Activation of monocytes/macrophages and tumor necrosis factor-α (TNF-α) activity are responsible for severe vascular injury in acute KD. We examined whether or not IVIG inhibits TNF-α-induced activation of transcription factor NF-κB, a factor that is essential for the expression of proinflammatory cytokines, in human monocytic U-937 cells. The inhibitory effect of IVIG on NF-κB activation induced by TNF-α was evaluated by Western blotting and flow cytometry. In addition, we examined the effect of IVIG on the expression of FcγIII (CD16) and FcγRIIb (CD32b) in U-937 cells and peripheral blood CD14+ monocytes/macrophages by flow cytometry. Western blotting demonstrated that IVIG inhibits NF-κB activation in U-937 cells, and flow cytometry that IVIG inhibits NF-κB activation in U-937 cells in a dose-related manner. Western blotting of cytoplasmic extracts of U-937 cells revealed that IVIG inhibited degradation of the IκBα protein. Moreover, flow cytometry demonstrated that IVIG decreased the expression of FcγRIII in U-937 cells and peripheral blood CD14+ monocytes/macrophages. However, Western blotting revealed that IVIG did not affect the quantity of FcγRIII protein, and PCR that IVIG did not affect the quantity of FcγRIII mRNA in the cells. These findings suggest that IVIG inhibits TNF-α-induced NF-κB activation in monocytes/macrophages, and blocks FcγRIII on the membranes of monocytes/macrophages.
KeywordsFcγRIIb FcγRIII Intravenous immunoglobulin Monocytes/macrophages NF-κB TNF-α
- Andersson J, Skansén-Saphir U, Sparrelid E, Andersson U (1996) Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 104 [Suppl 1]:10–20Google Scholar
- Ichiyama T, Ueno Y, Isumi H, Niimi A, Matsubara T, Furukawa S (2004) An immunoglobulin agent (IVIG) inhibits NF-κB activation in cultured endothelial cells of coronary artery in vitro. Inflamm Res (in press)Google Scholar
- Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP, Shulman ST, Wiggins JW, Hicks RV, Fulton DR, Lewis AB, Leung DYM, Colton T, Rosen FS, Melish ME (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315:341–347PubMedGoogle Scholar
- Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP, Mason WH, Meissner HC, Rowley AH, Shulman ST, Reddy V, Sundel RP, Wiggins JW, Colton T, Melish ME, Rosen FS (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633–1639PubMedGoogle Scholar
- Sugawara T, Hattori S, Hirose S, Furukawa S, Yabuta K, Shirai T (1987) Immunopathology of the skin lesions of Kawasaki disease. In: Schulman ST (ed) Kawasaki disease. Liss, New York, pp 185–192Google Scholar